Next Article in Journal
Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions
Next Article in Special Issue
Challenges, Solutions, and Quality Metrics of Personal Genome Assembly in Advancing Precision Medicine
Previous Article in Journal
Acknowledgement to Reviewers of Pharmaceutics in 2015
Previous Article in Special Issue
Genomic Discoveries and Personalized Medicine in Neurological Diseases
Article Menu

Export Article

Open AccessArticle
Pharmaceutics 2016, 8(1), 4; doi:10.3390/pharmaceutics8010004

Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma

Department of Biotechnology, Dr. M.G.R. Educational and Research Institute University, Chennai, Tamil Nadu 600095, India
*
Author to whom correspondence should be addressed.
Academic Editor: Huixiao Hong
Received: 1 November 2015 / Revised: 21 January 2016 / Accepted: 29 January 2016 / Published: 17 February 2016
(This article belongs to the Special Issue Personalized Medicine and Pharmacogenomics)
View Full-Text   |   Download PDF [925 KB, uploaded 17 February 2016]   |  

Abstract

Cytochrome P450 drug metabolizing enzymes are implicated in personalized medicine for two main reasons. First, inter-individual variability in CYP3A4 expression is a confounding factor during cancer treatment. Second, inhibition or induction of CYP3A4 can trigger adverse drug–drug interactions. However, inflammation can downregulate CYP3A4 and other drug metabolizing enzymes and lead to altered metabolism of drugs and essential vitamins and lipids. Little is known about effects of inflammation on expression of CYP450 genes controlling drug metabolism in the skin. Therefore, we analyzed seven published microarray datasets, and identified differentially-expressed genes in two inflammatory skin diseases (melanoma and psoriasis). We observed opposite patterns of expression of genes regulating metabolism of specific vitamins and lipids in psoriasis and melanoma samples. Thus, genes controlling the turnover of vitamin D (CYP27B1, CYP24A1), vitamin A (ALDH1A3, AKR1B10), and cholesterol (CYP7B1), were up-regulated in psoriasis, whereas melanomas showed downregulation of genes regulating turnover of vitamin A (AKR1C3), and cholesterol (CYP39A1). Genes controlling abnormal keratinocyte differentiation and epidermal barrier function (CYP4F22, SULT2B1) were up-regulated in psoriasis. The up-regulated CYP24A1, CYP4F22, SULT2B1, and CYP7B1 genes are potential drug targets in psoriatic skin. Both disease samples showed diminished drug metabolizing capacity due to downregulation of the CYP1B1 and CYP3A5 genes. However, melanomas showed greater loss of drug metabolizing capacity due to downregulation of the CYP3A4 gene. View Full-Text
Keywords: psoriasis; melanoma; microarray; CYP450; drug metabolism; personalized medicine psoriasis; melanoma; microarray; CYP450; drug metabolism; personalized medicine
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Sumantran, V.N.; Mishra, P.; Bera, R.; Sudhakar, N. Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma. Pharmaceutics 2016, 8, 4.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top